| Date Filed | Type | Description |
| 10/02/2023 |
4
| Thackray Helen M. (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 472 shares
@ $15.87, valued at
$7.5k
|
|
| 07/05/2023 |
4
| Thackray Helen M. (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 397 shares
@ $18.87, valued at
$7.5k
|
|
| 06/16/2023 |
4
| Thackray Helen M. (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 13,090 restricted stock units
@ $0
Granted 19,597 options to buy
@ $0 |
|
| 04/05/2023 |
4
| Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Sold 7,000 shares
@ $8.29, valued at
$58k
|
|
| 04/04/2023 |
4
| Thackray Helen M. (Director) has filed a Form 4 on ImmunoGen, Inc.|
Txns:
| Granted 1,953 shares
@ $3.84, valued at
$7.5k
|
|
| 12/21/2022 |
4
| Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 81,000 shares
@ $0
Granted 238,000 options to buy
@ $10.63, valued at
$2.5M
|
|
| 12/19/2022 |
4
| Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Sold 3,125 shares
@ $10.89, valued at
$34k
|
|
| 06/17/2022 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/04/2022 |
4
| Thackray Helen M. (Chief R&D Officer) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Sold 7,600 shares
@ $16.2, valued at
$123.1k
|
|
| 12/16/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/23/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/23/2021 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/02/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/14/2020 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/24/2020 |
4
| Thackray Helen M. (SVP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Granted 120,000 options to buy
@ $4.72, valued at
$566.4k
|
|
| 09/24/2019 |
4
| Thackray Helen M. (Director) has filed a Form 4 on BIOCRYST PHARMACEUTICALS INC|
Txns:
| Granted 40,000 options to buy
@ $2.86, valued at
$114.4k
|
|
| 09/24/2019 |
3
| Thackray Helen M. (Director) has filed a Form 3 on BIOCRYST PHARMACEUTICALS INC |
| 01/22/2019 |
4
| Thackray Helen M. (SVP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Granted 100,000 options to buy
@ $10.59, valued at
$1.1M
|
|
| 01/12/2018 |
4
| Thackray Helen M. (SVP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Granted 75,000 options to buy
@ $20.03, valued at
$1.5M
|
|
| 12/12/2017 |
4
| Thackray Helen M. (SVP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Sold 2,000 shares
@ $15.01, valued at
$30k
|
|
| 09/18/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/30/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 05/22/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 01/05/2017 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 10/04/2016 |
4
| Form 4 - Statement of changes in beneficial ownership of securities |
| 07/21/2016 |
4
| Thackray Helen M. (VP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Sold 2,000 shares
@ $8, valued at
$16k
|
|
| 07/06/2016 |
4
| Thackray Helen M. (VP Clinical Development, CMO) has filed a Form 4 on GLYCOMIMETICS INC|
Txns:
| Sold 5,068 shares
@ $7.4, valued at
$37.5k
Sold 10,136 shares
@ $7.01, valued at
$71.1k
Sold 6,796 shares
@ $6.68, valued at
$45.4k
|
|